Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence.

APOBEC Deaminases / genetics Adult Aged Aged, 80 and over Aldehyde Dehydrogenase, Mitochondrial / genetics Brazil / epidemiology China / epidemiology Esophageal Neoplasms / epidemiology Esophageal Squamous Cell Carcinoma / epidemiology Female Humans Incidence Iran / epidemiology Male Middle Aged Mutation Tumor Suppressor Protein p53 / genetics United Kingdom / epidemiology Whole Genome Sequencing

Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
11 2021
Historique:
received: 16 12 2020
accepted: 28 07 2021
pubmed: 20 10 2021
medline: 28 12 2021
entrez: 19 10 2021
Statut: ppublish

Résumé

Esophageal squamous cell carcinoma (ESCC) shows remarkable variation in incidence that is not fully explained by known lifestyle and environmental risk factors. It has been speculated that an unknown exogenous exposure(s) could be responsible. Here we combine the fields of mutational signature analysis with cancer epidemiology to study 552 ESCC genomes from eight countries with varying incidence rates. Mutational profiles were similar across all countries studied. Associations between specific mutational signatures and ESCC risk factors were identified for tobacco, alcohol, opium and germline variants, with modest impacts on mutation burden. We find no evidence of a mutational signature indicative of an exogenous exposure capable of explaining differences in ESCC incidence. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC)-associated mutational signatures single-base substitution (SBS)2 and SBS13 were present in 88% and 91% of cases, respectively, and accounted for 25% of the mutation burden on average, indicating that APOBEC activation is a crucial step in ESCC tumor development.

Identifiants

DOI: 10.1038/s41588-021-00928-6 PMID: 34663923
pubmed: 34663923
doi: 10.1038/s41588-021-00928-6
pii: 10.1038/s41588-021-00928-6
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0
ALDH2 protein, human EC 1.2.1.3
Aldehyde Dehydrogenase, Mitochondrial EC 1.2.1.3
APOBEC Deaminases EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1553-1563

Subventions

Organisme : NCI NIH HHS
ID : R21 CA191965
Pays : United States
Organisme : Cancer Research UK
ID : RG81771/84119
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C98/A24032
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Medical Research Council
ID : RG84369
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593 doi: 10.3322/caac.21492
Arnold, M., Soerjomataram, I., Ferlay, J. & Forman, D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64, 381–387 (2015).
pubmed: 25320104 doi: 10.1136/gutjnl-2014-308124
Abnet, C. C., Arnold, M. & Wei, W. Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018).
pubmed: 28823862 doi: 10.1053/j.gastro.2017.08.023
Murphy, G. et al. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann. Oncol. 28, 2086–2093 (2017).
pubmed: 28911061 pmcid: 5834011 doi: 10.1093/annonc/mdx279
Sheikh, M. et al. Individual and combined effects of environmental risk factors for esophageal cancer based on results from the Golestan Cohort Study. Gastroenterology 156, 1416–1427 (2019).
pubmed: 30611753 doi: 10.1053/j.gastro.2018.12.024
McCormack, V. A. et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific exposures to known and putative risk factors. Int. J. Cancer 140, 259–271 (2017).
pubmed: 27466161 doi: 10.1002/ijc.30292
Mello, F. W. et al. The synergistic effect of tobacco and alcohol consumption on oral squamous cell carcinoma: a systematic review and meta-analysis. Clin. Oral Investig. 23, 2849–2859 (2019).
pubmed: 31111280 doi: 10.1007/s00784-019-02958-1
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402–1407 (2015).
pubmed: 26551669 pmcid: 4783858 doi: 10.1038/ng.3441
Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354, 618–622 (2016).
pubmed: 27811275 pmcid: 6141049 doi: 10.1126/science.aag0299
Riva, L. et al. The mutational signature profile of known and suspected human carcinogens in mice. Nat. Genet. 52, 1189–1197 (2020).
pubmed: 32989322 pmcid: 7610456 doi: 10.1038/s41588-020-0692-4
Scelo, G. et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 5135 (2014).
pubmed: 25351205 doi: 10.1038/ncomms6135
Gao, Y. B. et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097–1102 (2014).
pubmed: 25151357 doi: 10.1038/ng.3076
Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 508, 91–95 (2014).
doi: 10.1038/nature13176
Zhang, L. et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 96, 597–611 (2015).
pubmed: 25839328 pmcid: 4385186 doi: 10.1016/j.ajhg.2015.02.017
Sawada, G. et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150, 1171–1182 (2016).
pubmed: 26873401 doi: 10.1053/j.gastro.2016.01.035
Kim, J. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–174 (2017).
doi: 10.1038/nature20805
Chang, J. et al. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat. Commun. 8, 15290 (2017).
Li, X. C. et al. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann. Oncol. 29, 938–944 (2018).
pubmed: 29351612 pmcid: 5913594 doi: 10.1093/annonc/mdy011
Mangalaparthi, K. K. et al. Mutational landscape of esophageal squamous cell carcinoma in an Indian cohort. Front. Oncol. 10, 1457 (2020).
pubmed: 32974170 pmcid: 7469928 doi: 10.3389/fonc.2020.01457
Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Preprint at bioRxiv https://doi.org/10.1101/2020.12.13.422570 (2020).
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017).
pubmed: 29056346 pmcid: 5720395 doi: 10.1016/j.cell.2017.09.042
Middlebrooks, C. D. et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat. Genet. 48, 1330–1338 (2016).
pubmed: 27643540 pmcid: 6583788 doi: 10.1038/ng.3670
Nik-Zainal, S. et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487–491 (2014).
pubmed: 24728294 pmcid: 4137149 doi: 10.1038/ng.2955
Kidd, J. M., Newman, T. L., Tuzun, E., Kaul, R. & Eichler, E. E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63 (2007).
Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
pubmed: 26432245 doi: 10.1038/nature15393
MacGregor, S. et al. Associations of ADH and ALDH2 gene variation with self report alcohol reactions, consumption and dependence: an integrated analysis. Hum. Mol. Genet. 18, 580–593 (2009).
pubmed: 18996923 doi: 10.1093/hmg/ddn372
Cui, R. et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 137, 1768–1775 (2009).
pubmed: 19698717 doi: 10.1053/j.gastro.2009.07.070
Wu, C. et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat. Genet. 43, 679–684 (2011).
pubmed: 21642993 doi: 10.1038/ng.849
Gao, Y. et al. Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case–control study. Cancer Epidemiol. 35, e91–e99 (2011).
Akbari, M. R. et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27, 1290–1296 (2008).
pubmed: 17724471 doi: 10.1038/sj.onc.1210739
Ko, J. M. Y. et al. BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. Int. J. Cancer 146, 1042–1051 (2020).
pubmed: 31396961 doi: 10.1002/ijc.32619
Deng, J. et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat. Commun. 8, 1533 (2017).
pubmed: 29142225 pmcid: 5688099 doi: 10.1038/s41467-017-01730-x
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
pubmed: 30337457 pmcid: 6298579 doi: 10.1126/science.aau3879
Yokoyama, A. et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565, 312–317 (2019).
pubmed: 30602793 doi: 10.1038/s41586-018-0811-x
Liu, X. et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology 153, 166–177 (2017).
pubmed: 28365443 doi: 10.1053/j.gastro.2017.03.033
Warnakulasuriya, S. et al. Carcinogenicity of opium consumption. Lancet Oncol. 21, 1407–1408 (2020).
doi: 10.1016/S1470-2045(20)30611-2
Balmain, A. The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk. Nat. Genet. 52, 1139–1143 (2020).
pubmed: 33106632 pmcid: 8360498 doi: 10.1038/s41588-020-00727-5
Bergmann, E. A., Chen, B. J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance and contamination estimator for matched tumor–normal pairs. Bioinformatics 32, 3196–3198 (2016).
pubmed: 27354699 pmcid: 5048070 doi: 10.1093/bioinformatics/btw389
Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data. Curr. Protoc. Bioinformatics 2016, 15.10.1–15.10.18 (2016).
Raine, K. M. et al. cgpPindel: identifying somatically acquired insertion and deletion events from paired end sequencing. Curr. Protoc. Bioinformatics 52, 15.7.1–15.7.12 (2015).
doi: 10.1002/0471250953.bi1507s52
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
pubmed: 30013048 doi: 10.1038/s41592-018-0051-x
Bergstrom, E. N. et al. SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genomics 20, 685 (2019).
pubmed: 31470794 pmcid: 6717374 doi: 10.1186/s12864-019-6041-2
Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020).
pubmed: 32118208 pmcid: 7048622 doi: 10.1038/s43018-020-0027-5
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866 doi: 10.1038/nature17676
Senkin, S. MSA: reproducible mutational signature attribution with confidence based on simulations. Preprint at bioRxiv https://doi.org/10.1101/2020.12.14.422764 (2020).
Buisson, R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, eaaw2872 (2019).
pubmed: 31249028 pmcid: 6731024 doi: 10.1126/science.aaw2872
Bergstrom, E. N., Barnes, M., Martincorena, I. & Alexandrov, L. B. Generating realistic null hypothesis of cancer mutational landscapes using SigProfilerSimulator. BMC Bioinformatics 21, 438 (2020).
Mas-Ponte, D. & Supek, F. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. Nat. Genet. 52, 958–968 (2020).
pubmed: 32747826 pmcid: 7610516 doi: 10.1038/s41588-020-0674-6
Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
pubmed: 22608084 pmcid: 3414841 doi: 10.1016/j.cell.2012.04.024
Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
pubmed: 25722852 pmcid: 4342193 doi: 10.1186/s13742-015-0047-8
Nasrollahzadeh, D. et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br. J. Cancer 98, 1857–1863 (2008).
pubmed: 18475303 pmcid: 2410115 doi: 10.1038/sj.bjc.6604369

Auteurs

Sarah Moody (S)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
ORCID: 0000-0003-4904-1041

Sergey Senkin (S)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
ORCID: 0000-0001-5848-005X

S M Ashiqul Islam (SMA)

Moores Cancer Centre, UC San Diego Health, La Jolla, CA, USA.
Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA.
Department of Bioengineering, University of California, La Jolla, CA, USA.

Jingwei Wang (J)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
ORCID: 0000-0002-0201-2369

Dariush Nasrollahzadeh (D)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Ricardo Cortez Cardoso Penha (R)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Stephen Fitzgerald (S)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

Erik N Bergstrom (EN)

Moores Cancer Centre, UC San Diego Health, La Jolla, CA, USA.
Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA.
Department of Bioengineering, University of California, La Jolla, CA, USA.

Joshua Atkins (J)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Yudou He (Y)

Moores Cancer Centre, UC San Diego Health, La Jolla, CA, USA.
Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA.
Department of Bioengineering, University of California, La Jolla, CA, USA.

Azhar Khandekar (A)

Moores Cancer Centre, UC San Diego Health, La Jolla, CA, USA.
Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA.
Department of Bioengineering, University of California, La Jolla, CA, USA.

Karl Smith-Byrne (K)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
ORCID: 0000-0002-1932-7463

Christine Carreira (C)

Evidence Synthesis and Classification Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Valerie Gaborieau (V)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Calli Latimer (C)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

Emily Thomas (E)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
ORCID: 0000-0002-4563-8695

Irina Abnizova (I)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

Pauline E Bucciarelli (PE)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

David Jones (D)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
ORCID: 0000-0002-0407-0386

Jon W Teague (JW)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

Behnoush Abedi-Ardekani (B)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
ORCID: 0000-0002-0980-0587

Stefano Serra (S)

University Health Network, Toronto, Ontario, Canada.

Jean-Yves Scoazec (JY)

Department Laboratory Medicine and Pathology, Gustave Roussy, Paris, France.

Hiva Saffar (H)

Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Farid Azmoudeh-Ardalan (F)

Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Masoud Sotoudeh (M)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Arash Nikmanesh (A)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Hossein Poustchi (H)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Ahmadreza Niavarani (A)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Samad Gharavi (S)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Michael Eden (M)

Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.

Paul Richman (P)

Histopathology Department, Hemel Hempstead General Hospital, Hemel Hempstead, UK.

Lia S Campos (LS)

West Suffolk NHS Foundation Trust, Bury St Edmunds, UK.

Rebecca C Fitzgerald (RC)

MRC Cancer Unit, University of Cambridge, Cambridge, UK.
ORCID: 0000-0002-3434-3568

Luis Felipe Ribeiro (LF)

Brazilian National Cancer Institute, Rio de Janeiro, Brazil.

Sheila Coelho Soares-Lima (SC)

Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
ORCID: 0000-0002-6742-3708

Charles Dzamalala (C)

University of Malawi, Zomba, Malawi.

Blandina Theophil Mmbaga (BT)

Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre & Kilimanjaro Christian Medical University College, Moshi, Tanzania.
ORCID: 0000-0002-5550-1916

Tatsuhiro Shibata (T)

Division of Cancer Genomics, National Cancer Centre Research Institute, Tokyo, Japan.
ORCID: 0000-0002-0477-210X

Diana Menya (D)

Moi University, Mombasa, Kenya.

Alisa M Goldstein (AM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA.
ORCID: 0000-0002-7538-3582

Nan Hu (N)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA.

Reza Malekzadeh (R)

Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.
ORCID: 0000-0002-9820-6335

Abdolreza Fazel (A)

Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

Valerie McCormack (V)

Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

James McKay (J)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Sandra Perdomo (S)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Ghislaine Scelo (G)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Estelle Chanudet (E)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Laura Humphreys (L)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

Ludmil B Alexandrov (LB)

Moores Cancer Centre, UC San Diego Health, La Jolla, CA, USA.
Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA.
Department of Bioengineering, University of California, La Jolla, CA, USA.

Paul Brennan (P)

Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
ORCID: 0000-0002-0518-8714

Michael R Stratton (MR)

Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. mrs@sanger.ac.uk.
ORCID: 0000-0001-6035-153X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Aminohydrolases › Nucleoside deaminases › Cytidine deaminase › APOBEC Deaminases › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines mitochondriales › Aldehyde dehydrogenase, mitochondrial › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Sud › Brésil › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Régions géographiques › Asie › Extrême-Orient › Chine › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Carcinome épidermoïde de l'oesophage › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Régions géographiques › Asie › Asie de l'Ouest › Moyen Orient › Iran › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Régions géographiques › Europe › Royaume-Uni › Mutational signatures in esophageal squamous...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Séquençage du génome entier › Mutational signatures in esophageal squamous...